Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.
Treatment of lymphomas with 131I-Lym-1 (Meeting abstract).
Fourth Annual Symposium: Current Status and Future Directions of Immunoconjugates. Diagnostic and Therapeutic Applications in Benign and Malignant Disorders. January 23-26, 1992, Key Biscayne, FL, p. 68, 1992.. Unique Identifier : AIDSLINE ICDB/93690321 DeNardo GL; Univ. of California Davis, Molecular Cancer Inst., 1508 Alhambra; Blvd., Sacramento, CA 95816
Abstract:
The development of monoclonal antibodies has stimulated new interest in their use for specific targeting as vehicles for the diagnosis and treatment of cancer. While this approach is analogous to the use of chemotherapy, it has the advantage of specific targeting to the cancer. While targeting of all of the antibody to the cancer is conceptually feasible, only a 1000- to 10,000-fold greater targeting of the antibody has been achieved in patients (pts) when compared with the distribution of drugs. Activities at the University of California Davis (UCD) began 12 yr ago. The first pt with lymphoma to be treated with radiolabeled antibody was at UCD 6 yr ago. Since that time, about 60 pts with B-cell malignancies (NHL and CLL) that were refractory to conventional treatment have been treated with radiolabeled antibodies, and about two thirds of these pts have durably responded to this treatment. Almost one half of these responders have had a complete disappearance of disease. B-cell malignancies are particularly well suited to this form of treatment, because they are often multicentric and incurable at the time of initial presentation, 50% are incurable by conventional methods, the malignant cells are particularly radiosensitive, and the pts are anergic and unlikely to react to the foreign antibody molecule. Toxicity can be categorized to be of two general types: that secondary to the antibody and that secondary to the radiation. The former has been transient; occurs on the day of treatment; consists of hives, chills, fever, tachycardia and (rarely) hypotension; and has not limited treatment. Myelosuppression secondary to radiation has been the factor that impedes achievement of cure in these pts, as indicated earlier. Strikingly, there has been no long-term toxicity associated with this treatment other than the myelosuppression. Because there are a great many opportunities for improving upon these encouraging results, there is reason to believe that the next 30 yr will show increasing use of antibodies for treating cancer as well as other disorders.
Keywords: Antibodies, Monoclonal/*THERAPEUTIC USE Human Iodine Radioisotopes/*THERAPEUTIC USE Lymphoma, Non-Hodgkin's/*THERAPY Lymphoma, Small-Cell/*THERAPY *Radioimmunotherapy ABSTRACT 930630
M9361083
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.
